Morepen Labs.

Who are the top shareholders of the Morepen Labs.?

The top shareholders of Morepen Labs include Pinfold Overseas Limited with 7.03%, Scope Credits And Financial Services Pvt. Ltd. at 2.84%, and individual investors collectively holding 48.76%. There are also 44 Foreign Institutional Investors with 1.94% and no pledged promoter holdings.

The top shareholders of Morepen Labs include a mix of individual and institutional investors. The largest public shareholder is Pinfold Overseas Limited, holding 7.03%. Among the promoters, Scope Credits And Financial Services Pvt. Ltd. has the highest stake at 2.84%. Additionally, individual investors collectively hold a significant portion of 48.76%. There are also 44 Foreign Institutional Investors (FIIs) with a combined holding of 1.94%, and two mutual fund schemes that hold 0.0%. Notably, there are no pledged promoter holdings.

What does Morepen Labs. do?

Morepen Laboratories Limited is an Indian pharmaceutical company specializing in the Pharmaceuticals & Biotechnology sector, with a market cap of Rs 3,517 Cr and reported net sales of 466 Cr and net profit of 20 Cr for March 2025. Key metrics include a P/E ratio of 30.00 and a return on equity of 10.21%.

Overview:<BR>Morepen Laboratories Limited is an India-based pharmaceutical company operating in the Pharmaceuticals & Biotechnology industry, categorized as a Small Cap.<BR><BR>History:<BR>Morepen Laboratories was incorporated in the past, with the latest quarterly results reported for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 466 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 20 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap value: Rs 3,517 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 30.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: -0.02<BR>- Return on Equity: 10.21%<BR>- Price to Book: 3.05<BR><BR>Contact Details:<BR>Address: Morepen Village, Nalagarh Road Near Baddi Solan Himachal Pradesh : 173205<BR>Tel: 91-01795-276201-03<BR>Email: investors@morepen.com<BR>Website: http://www.morepen.com

Has Morepen Labs. declared dividend?

No Dividend History Available

Who are the peers of the Morepen Labs.?

Peers of Morepen Labs include Guj. Themis Bio., Gufic BioScience, Orchid Pharma, Advanced Enzyme, Indoco Remedies, Senores Pharma, IOL Chemicals, Panacea Biotec, Novartis India, and Zota Health Care. Morepen Labs has average management risk and a 1-year return of 9.77%, which is higher than Orchid Pharma's -34.27% but lower than Panacea Biotec's 215.30%.

Peers: The peers of Morepen Labs. are Guj. Themis Bio., Gufic BioScience, Orchid Pharma, Advanced Enzyme, Indoco Remedies, Senores Pharma., IOL Chemicals, Panacea Biotec, Novartis India, and Zota Health Care.<BR><BR>Quality Snapshot: Excellent management risk is observed at Guj. Themis Bio., Gufic BioScience, and Advanced Enzyme, while Average management risk is found at Morepen Labs., Indoco Remedies, IOL Chemicals, and Novartis India. Below Average management risk is present at Orchid Pharma, Senores Pharma., and Panacea Biotec. Growth is rated as Excellent for Senores Pharma., Good for Morepen Labs. and Novartis India, Average for Gufic BioScience, and Below Average for Guj. Themis Bio., Orchid Pharma, Advanced Enzyme, Indoco Remedies, IOL Chemicals, and Panacea Biotec. Capital Structure is Excellent for Guj. Themis Bio., Gufic BioScience, Advanced Enzyme, IOL Chemicals, and Novartis India, Average for Indoco Remedies, and Below Average for Orchid Pharma, Senores Pharma., and Panacea Biotec.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Panacea Biotec at 215.30%, while the lowest is Orchid Pharma at -34.27%. Morepen Labs.'s 1-year return of 9.77% is significantly higher than that of Orchid Pharma but lower than that of Panacea Biotec. Additionally, Orchid Pharma and Panacea Biotec have negative six-month returns.

Who are in the management team of Morepen Labs.?

As of March 2023, the management team of Morepen Labs includes Sushil Suri (Chairman & Managing Director), Sanjay Suri (Whole-time Director), and several Non-Executive & Independent Directors: Manoj Joshi, Bhupender Raj Wadhwa, Sukhcharan Singh, Praveen Kumar Dutt, and Savita, along with Vipul Kumar Srivatava as Company Secretary & Compliance Officer.

As of March 2023, the management team of Morepen Labs includes the following individuals:<BR><BR>1. Sushil Suri - Chairman & Managing Director<BR>2. Manoj Joshi - Non-Executive & Independent Director<BR>3. Bhupender Raj Wadhwa - Non-Executive & Independent Director<BR>4. Sukhcharan Singh - Non-Executive & Independent Director<BR>5. Vipul Kumar Srivatava - Company Secretary & Compliance Officer<BR>6. Sanjay Suri - Whole-time Director<BR>7. Praveen Kumar Dutt - Non-Executive & Independent Director<BR>8. Savita - Non-Executive & Independent Director<BR><BR>Each member plays a distinct role in the governance and management of the company.

How big is Morepen Labs.?

As of 24th July, Morepen Laboratories Ltd has a market capitalization of 3,404.00 Cr, with net sales of 1,811.58 Cr and a net profit of 118.03 Cr reported in the latest four quarters. Shareholder's funds are 847.23 Cr, and total assets amount to 1,293.21 Cr as of March 2024.

As of 24th July, Morepen Laboratories Ltd has a market capitalization of 3,404.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Morepen Laboratories Ltd reported net sales of 1,811.58 Cr and a net profit of 118.03 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with shareholder's funds amounting to 847.23 Cr and total assets of 1,293.21 Cr.

Is Morepen Labs. overvalued or undervalued?

As of November 17, 2025, Morepen Labs is fairly valued with a PE ratio of 33.58, lower than Sun Pharma's 36.69 but higher than Cipla's 22.81, and has a low PEG ratio of 0.00, while underperforming the Sensex with a stock return of -38.87%.

As of 17 November 2025, Morepen Labs has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 33.58, an EV to EBITDA of 19.59, and a Price to Book Value of 2.12. <BR><BR>In comparison with its peers, Morepen Labs' PE ratio is lower than that of Sun Pharma, which stands at 36.69, but higher than Cipla's attractive valuation of 22.81. The PEG ratio for Morepen is notably low at 0.00, indicating potential growth concerns compared to peers like Divi's Lab, which has a PEG of 1.97. Additionally, Morepen Labs has underperformed the Sensex significantly over the past year, with a stock return of -38.87% compared to the Sensex's 9.50%.

Is Morepen Labs. technically bullish or bearish?

As of November 19, 2025, Morepen Labs is in a bearish trend with moderate strength, supported by bearish MACD and moving averages, while showing mixed signals from KST and underperforming against the Sensex.

As of 19 November 2025, the technical trend for Morepen Labs has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD is bearish, and the daily moving averages confirm this bearish outlook. Bollinger Bands are also indicating a bearish trend on both weekly and monthly time frames. The KST shows a mildly bullish signal on the weekly but is mildly bearish on the monthly, indicating some mixed signals. Overall, the Dow Theory supports a mildly bearish view on both weekly and monthly time frames. The stock has underperformed significantly against the Sensex over various periods, further reinforcing the bearish sentiment.

How has been the historical performance of Morepen Labs.?

Morepen Labs has shown consistent growth in net sales and profitability, with net sales increasing from 768.54 crore in March 2019 to 1,811.58 crore in March 2025, and profit after tax rising from 28.84 crore to 118.02 crore in the same period. The company's total assets and liabilities also grew significantly, reflecting robust expansion.

Answer:<BR>The historical performance of Morepen Labs shows a consistent growth trajectory in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Morepen Labs has demonstrated significant growth in net sales, increasing from 768.54 crore in March 2019 to 1,811.58 crore in March 2025. The total operating income followed a similar trend, reaching 1,811.58 crore in March 2025, up from 853.07 crore in March 2020. The company's operating profit (PBDIT) also improved, rising to 192.43 crore in March 2025 from 71.19 crore in March 2019. Profit before tax increased to 155.11 crore in March 2025, compared to 29.18 crore in March 2019, while profit after tax reached 118.02 crore in March 2025, up from 28.84 crore in March 2019. The company's total assets grew significantly from 663.46 crore in March 2020 to 1,778.10 crore in March 2025, reflecting a robust expansion. Total liabilities also increased, from 663.46 crore in March 2020 to 1,778.10 crore in March 2025, indicating a rise in borrowings and other obligations. Cash flow from operating activities showed fluctuations, with a net cash inflow of 10 crore in March 2025, following a net outflow in the previous year. Overall, Morepen Labs has shown a strong upward trend in sales and profitability, alongside an increase in total assets and liabilities over the years.

When is the next results date for Morepen Laboratories Ltd?

The next results date for Morepen Laboratories Ltd is 10 February 2026.

The next results date for Morepen Laboratories Ltd is scheduled for 10 February 2026.

Are Morepen Laboratories Ltd latest results good or bad?

Morepen Laboratories Ltd's latest results show strong revenue growth with a record ₹484.16 crores for Q3 FY26, but a significant 32.69% decline in net profit raises concerns about profitability and investor confidence. Overall, the mixed signals suggest caution for potential investors.

Morepen Laboratories Ltd's latest results present a mixed picture. On one hand, the company achieved its highest-ever quarterly revenue of ₹484.16 crores for Q3 FY26, reflecting a strong sequential growth of 17.63% and a year-on-year increase of 6.93%. This indicates robust demand across its product portfolio, particularly in therapeutic categories such as antibiotics and respiratory products.<BR><BR>However, the profitability aspect raises concerns. The net profit for the quarter was ₹27.51 crores, which represents a significant decline of 32.69% compared to the previous quarter. This drop in profit is attributed to a higher effective tax rate and increased depreciation charges, leading to a PAT margin contraction to 5.68% from 9.97% in the prior quarter.<BR><BR>While the operating margin improved to 9.57%, the overall financial performance suggests challenges in translating revenue growth into sustainable profitability. Additionally, the stock has underperformed significantly over the past year, declining 31.65%, which reflects investor concerns about the company's growth trajectory and operational efficiency.<BR><BR>In summary, while Morepen Laboratories has demonstrated strong revenue growth, the substantial drop in net profit and ongoing concerns about capital efficiency and investor confidence indicate that the latest results are more negative than positive. Investors may want to approach the stock with caution given these mixed signals.

Should I buy, sell or hold Morepen Laboratories Ltd?

Which are the latest news on Morepen Labs.?

Why is Morepen Laboratories Ltd falling/rising?

As of 16-May, Morepen Laboratories Ltd's stock price is declining, currently at 41.96, with a significant drop of -31.18% over the past year and a concerning decrease in investor participation. The stock's poor financial health and underperformance compared to its sector contribute to the negative sentiment surrounding it.

As of 16-May, Morepen Laboratories Ltd's stock price is falling, currently at 41.96, reflecting a change of -0.94 (-2.19%). The stock has been underperforming, with a consecutive decline over the last two days, resulting in a total drop of -4.55% during this period. This trend is compounded by the fact that the stock has underperformed its sector by -2.49% today.<BR><BR>In terms of broader performance, the stock has seen a significant decline over the past year, with a return of -31.18%, which is substantially worse than the market's average decline of -8.84%. Additionally, the stock's performance over the last week shows a decrease of -8.16%, compared to the Sensex's decline of -2.70%. <BR><BR>Investor participation has also been decreasing, as evidenced by a 45.34% drop in delivery volume compared to the 5-day average. This suggests a lack of confidence among investors, which is further supported by the company's poor long-term growth metrics, including a net sales growth rate of only 10.03% and an operating profit growth rate of 5.12% over the last five years.<BR><BR>Moreover, the company's financial health indicators are concerning, with a return on capital employed (ROCE) at a low of 8.16% and a return on equity (ROE) of 6.3. The stock is trading at a premium compared to its peers, with a price-to-book value of 1.9, indicating an expensive valuation. The recent financial results show a significant decline in profits, with a -39.5% drop over the past year, which has likely contributed to the negative sentiment surrounding the stock.<BR><BR>Overall, the combination of declining stock performance, reduced investor participation, and poor financial indicators has led to the current downward trend in Morepen Laboratories Ltd's stock price.